9M and Q3 2025 Results

Conference call and webcast for investors and analysts

6 November 2025

Cautionary statements regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial position.

9M and Q3 2025 Results

Conference call agenda

CEO Opening Remarks	**Pascal Soriot** Chief Executive Officer	
Financial Results	**Aradhana Sarin** Chief Financial Officer	
Oncology Haematology	**Dave Fredrickson** EVP, Oncology Haematology Business	**Susan Galbraith** EVP, Oncology Haematology R&D
BioPharmaceuticals	**Ruud Dobber** EVP, BioPharmaceuticals Business	**Sharon Barr** EVP, BioPharmaceuticals R&D
Rare Disease	**Marc Dunoyer** Chief Executive Officer, Alexion	
CEO Closing Remarks, Q&A	**Pascal Soriot** Chief Executive Officer	



CEO Opening Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER

Continued strong commercial performance in 9M 2025 and unprecedented pipeline delivery

Sustained commercial momentum

+11% Total Revenue[1]

+15% Core EPS[1]

31 new approvals in key regions
since FY 2024 results[2]

Delivered high-impact readouts

16 positive Phase III readouts
since FY 2024 results[3]

6 plenary presentations at major conferences
YTD[4]

All growth rates at CER. 1. Growth rates relative to 2024 performance. 2. Key regions – US, EU, Japan, China. 3. Reflects first data readout from a Phase III trial. Includes SERENA-6, CALYPSO, DESTINY-Gastric04, DESTINY-Breast09, KALOS, LOGOS, DESTINY-Breast11, POTOMAC, NATRON, BaxHTN, PREVAIL, AZALEA, TULIP-SC, DESTINY-Breast05, TROPION-Breast02, Bax24. 4. Plenary (ASCO and WCLC) or Presidential (ESMO) session.
Appendix: Glossary.

9M 2025 – growth driven by global reach and diverse sources of business

9M 2025 | % Total Revenue by therapy area



9M 2025 | % Total Revenue by geography



Strength across therapy areas

9M 2025 | Total Revenue ($m)[1]



Growth across geographies

9M 2025 | Total Revenue ($m)[1]



Due to rounding, the sum of the percentages may not agree to totals. 1. All growth rates at CER.
Appendix: Glossary.

Continued momentum delivering across diverse pipeline

Key Phase III trial readouts in 2025 to date drive growth to 2030 and beyond

Oncology

SERENA-6 NME
camizestrant

MATTERHORN
Imfinzi

DESTINY-Breast09
Enhertu

DESTINY-Breast05
Enhertu reinforcing potential as foundational treatment in early-stage HER2+ BC

POTOMAC
Imfinzi

DESTINY-Breast11
Enhertu

FLAURA2 OS
Tagrisso

TROPION-Breast02
Datroway redefining management of patients with 1L TNBC not suitable for IO

BioPharmaceuticals

KALOS/LOGOS
Breztri

BaxHTN | Bax24 NME
baxdrostat potential first-in-class ASI addressing hard-to-treat hypertension

TULIP-SC
Saphnelo convenient dosing with self-administration for SLE

Rare Disease

CARES NME
anselamimab

PREVAIL NME
gefurulimab

Readouts across 2025 represent combined risk-adjusted >$10bn opportunity[1]

Indicates readout from 29 July 2025 to 6 November 2025. 1. Combined risk-adjusted Peak-Year Revenue of all anticipated readouts in 2025, including those depicted on the slide. Individual PYR may occur at different timepoints for different trials.
Collaboration partners: Daiichi Sankyo (*Enhertu, Datroway*).
Appendix: Glossary.

Strengthening operations in US to power future growth

Investments support $80bn Total Revenue ambition by 2030

Voluntary agreement with US Government

- Provides greater clarity around pricing and 3-year exemption from tariffs
- MFN pricing for existing medicines in Medicaid and prospective equalisation for new medicines
- Direct to consumer sales

Expanded US footprint

- New $5bn manufacturing investments in Virginia/Texas
- 13[1] manufacturing sites in US
- Supports domestic sourcing and accelerates pipeline delivery

Harmonised global listing

- Direct listing of AZN ordinary shares in the US on the NYSE
- Provides access to broadest available pool of capital
- 99.36% shareholder vote in favour at GM on 3 November

Expanding manufacturing footprint in US

1. Includes 2 sites dedicated to clinical supply.
Map excludes facilities outside of the US.
Appendix: Glossary.



Financial Results

Aradhana Sarin
CHIEF FINANCIAL OFFICER

9M and Q3 2025 – Reported profit and loss

	9M 2025 $m	CER change %	% Total Revenue	Q3 2025 $m	CER change %	% Total Revenue
- Product Sales	*41,035*	*9*	*95*	*14,365*	*9*	*95*
- Alliance Revenue	*2,108*	*41*	*5*	*815*	*44*	*5*
Product Revenue	**43,143**	**11**	**100**	**15,180**	**11**	**100**
- Collaboration Revenue	*93*	*(15)*	*-*	*11*	*(82)*	*-*
Total Revenue	**43,236**	**11**	**100**	**15,191**	**10**	**100**
Gross Margin	*83%*	*+1p*		*82%*	*+4p*	
- R&D expense	(10,370)	16	24	(3,663)	16	24
- SG&A expense	(14,441)	(1)	33	(5,085)	(3)	33
Total operating expense[1]	(25,237)	6	58	(8,896)	4	59
Other operating income and expense	281	87	1	89	>3x	1
Operating profit	10,765	35	25	3,583	64	24
Tax rate	19%			22%		
Reported EPS	**$5.10**	**42**		**$1.64**	**70**	

Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

9M and Q3 2025 – Core profit and loss

	9M 2025 $m	CER change %	% Total Revenue	Q3 2025 $m	CER change %	% Total Revenue
- Product Sales	*41,035*	*9*	*95*	*14,365*	*9*	*95*
- Alliance Revenue	*2,108*	*41*	*5*	*815*	*44*	*5*
Product Revenue	**43,143**	**11**	**100**	**15,180**	**11**	**100**
- Collaboration Revenue	*93*	*(15)*	*-*	*11*	*(82)*	*-*
Total Revenue	**43,236**	**11**	**100**	**15,191**	**10**	**100**
Gross Margin	*83%*	*-*		*82%*	*-*	
- R&D expense	(10,091)	16	23	(3,550)	14	23
- SG&A expense	(11,081)	3	26	(3,822)	4	25
Total operating expense[1]	(21,598)	9	50	(7,520)	9	50
Other operating income and expense	282	91	1	96	>3x	1
Operating profit	14,380	13	33	4,993	13	33
Tax rate	19%			21%		
Core EPS	**$7.04**	**15**		**$2.38**	**12**	

Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

FY 2025 guidance reiterated

Net cash inflow from operating activities increased by 37% in 9M 2025

Net debt/EBITDA 1.2x



Capital allocation priorities remain unchanged

FY 2025 guidance (CER)

Total Revenue
anticipated to increase by a **high single-digit** percentage

Core EPS
anticipated to increase by a **low double-digit** percentage

- Core tax rate expected to be between 18-22%
- Anticipated FX impact[5] – neutral on Total Revenue and Core EPS

Due to rounding, the sum of the dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible assets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), movement in profit participation liability, purchase and disposal of non-current asset investments, payments to associates and joint ventures, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt and payment of contingent consideration on business combinations. The Company mainly uses debt issuance or available cash to finance new Business Development opportunities. 3. Comprises mainly shares purchased by Employee Benefit Trust. 4. Rolling 12-month EBITDA. AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A1, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 5. If foreign exchange rates for October 2025 to December 2025 were to remain at the average rates seen in September 2025. Appendix: Glossary.

Oncology

Dave Fredrickson
ONCOLOGY HAEMATOLOGY BUSINESS

Susan Galbraith
ONCOLOGY HAEMATOLOGY R&D

Oncology – 9M and Q3 2025

Total Revenue +16% in 9M 2025 driven by strong global demand across medicines

Oncology

9M 2025 $18.6bn, +16%



Q3 2025: key dynamics

- ***Tagrisso*** +10%, demand across indications, leadership in 1L combination market
- ***Calquence*** +11%, solidified position as leading BTKi in 1L CLL in major markets
- ***Lynparza* PR** +5%, sustained PARPi leadership
- ***Truqap*** +54%, continued demand growth in 2L biomarker-altered population
- ***Imfinzi*** +31%, broad demand growth, strong launches in lung and bladder cancers
- ***Imjudo*** +14%, further demand in HCC
- ***Enhertu*** +39%, uptake in CTx-naïve HER2-low mBC, CN growth post-NRDL inclusion
- ***Datroway*** $24m, increasing penetration in HR+ HER2- breast cancer and early uptake post-US launch in previously-treated advanced *EGFR*m lung cancer

Key regulatory approvals:

- JP (*Calquence* ECHO, *Enhertu* DESTINY-Breast06, *Imfinzi* NIAGARA, AEGEAN), CN (*Datroway* TROPION-Breast01, *Lynparza* PROpel)

1. Others is inclusive of *Datroway*.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Merck & Co., Inc. (*Lynparza*), Hutchmed (*Orpathys*).
Appendix: Glossary.

Oncology – paradigm-shifting Phase III data presentations

Data at ESMO reinforce our ambition to transform care in breast and bladder cancers

Redefining care across breast cancer

Moving *Enhertu* into early HER2+ breast cancer

DESTINY-Breast11

Neoadjuvant *Enhertu* → THP
High-risk HER2+ eBC

- **67% pCR** with early trend to EFS benefit
- **Highest reported pCR** rate seen in a Phase III registrational trial in this setting

DESTINY-Breast05

Post-neoadjuvant *Enhertu*
High-risk HER2+ eBC

- **53% reduction** in risk of disease recurrence or death vs T-DM1
- **>92% patients free of invasive disease** at 3 years

Broadening potential of *Datroway*

TROPION-Breast02

Datroway
1L TNBC not suitable for PDx

- **Unprecedented mOS improvement** of 5 mo vs CTx
- **Robust anti-tumour activity** with 63% ORR

Driving new approaches in bladder cancer

Moving *Imfinzi* into earlier disease

POTOMAC

***Imfinzi* + BCG (I+M)**
High-risk NMIBC

- **32% reduction** in risk of disease recurrence or death vs BCG (I+M)
- **Early and sustained DFS benefit** starting at <4 mo

Collaboration partners: Daiichi Sankyo (*Enhertu, Datroway*).
Appendix: Glossary.

BioPharmaceuticals

Ruud Dobber
BIOPHARMACEUTICALS BUSINESS

Sharon Barr
BIOPHARMACEUTICALS R&D

BioPharmaceuticals – 9M and Q3 2025

Total Revenue $17.1bn in 9M 2025 driven by strong momentum in key medicines

CVRM

9M 2025 $9.8bn, +5%



R&I

9M 2025 $6.5bn, +13%



Q3 2025: key dynamics

- ***Farxiga*** +8%, global demand growth mainly driven by CKD and HF
- ***Lokelma*** +30%, market leader in growing K^+ binder class in hyperkalaemia
- ***Brilinta*** (56%), generic erosion
- ***Fasenra*** +20%, sustained IL-5 leadership in asthma; China and EGPA launches
- ***Tezspire*** +47%, continued launch momentum
- ***Breztri*** +20%, fastest growing medicine in expanding FDC triple class in COPD
- ***Saphnelo*** +44%, increasing penetration in i.v. segment of SLE
- **V&I** (11%); PR +2%, ***Beyfortus*** (1%); PR +29%

Key regulatory approvals:
US, EU (*Tezspire* nasal polyps)

Collaboration partners: Amgen (*Tezspire*); Sanofi (*Beyfortus*); Ionis (*Wainua*).
Appendix: Glossary.

BioPharmaceuticals – best-in-class profile with baxdrostat

Potential first-in-class aldosterone inhibitor for uncontrolled and resistant hypertension

BaxHTN Phase III data at ESC | Robust mmHg reduction with baxdrostat in uncontrolled and treatment resistant hypertension



Largest mmHg reduction reported in primary analysis

Powerful aldosterone synthase inhibition with long half-life

Favourable tolerability and side-effect profile

Positive Bax24 readout

Statistically significant and **highly clinically meaningful** reduction in ambulatory 24-hour average SBP vs placebo at 12 weeks

Efficacy observed through 24-hour period, including early morning when patients at highest risk of CV events

AHA 2025 | 9 Nov

$5bn+ PYR[2] opportunity across monotherapy and combinations

1. P<0.0001. 2. P<0.0001 2. Peak-Year Revenue, non-risk adjusted.
Appendix: Glossary.

Rare Disease

Marc Dunoyer
CHIEF EXECUTIVE OFFICER, ALEXION

Rare Disease – 9M and Q3 2025

Total Revenue $6.8bn in 9M 2025 driven by patient demand across the portfolio



Q3 2025: key dynamics

C5 Franchise

- ***Ultomiris*** +17%, demand growth across indications, including within the competitive gMG and PNH markets
- ***Soliris*** (24%), continued successful conversion to *Ultomiris* across indications and additional impact from biosimilars in US and EU

Beyond Complement

- ***Strensiq*** +28%, continued strong global demand from patients with HPP
- ***Koselugo*** +79%, driven by continued global demand and favourable timing for tender orders in Emerging Markets

Key regulatory approvals:

JP, EU (*Koselugo* NF1-PN adults); CN (*Ultomiris* NMOSD)

All growth rates at CER. 1. *Ultomiris* Total Revenue includes sales of Voydeya. 2. Other includes *Kanuma* and *Beyonttra* (JP only).
Collaboration partners: Merck & Co., Inc. (*Koselugo*) concluded in August 2025, BridgeBio (*Beyonttra*).
Appendix: Glossary.

Rare Disease – Phase III data and progress to date

Reinforcing innovation and leadership in Rare Disease

PREVAIL Phase III data at AANEM | Rapid, complete and sustained complement inhibition with gefurulimab in gMG



>80% | gMG patients not treated with branded medicines today

1st | Potential first autoinjector in gMG

Key Phase III progress in 2025

eneboparatide

- Analysis ongoing for 52-week data from **CALYPSO**
- Continuing to monitor patients in OLE

anselamimab

- Plan to submit the pre-specified subgroup analysis from **CARES 301/2** with regulatory authorities

efzimfotase alfa

- **MULBERRY**, **HICKORY, CHESTNUT** data anticipated H1 2026

***P<0.001; 2-sided nominal P values are reported for weeks 1-23 for the comparison of change from baseline between treatment groups.
1. Baseline is defined as the last available assessment value prior to the first dose of study intervention.
Appendix: Glossary.

CEO Closing Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER

Executing in unprecedented catalyst rich period and on track for 2030 ambition

H1 2025

- **DESTINY-Breast09 |** *Enhertu* — 1L HER2+ breast cancer
- **DESTINY-Breast11 |** *Enhertu* — early-stage HER2+ breast cancer
- **MATTERHORN |** *Imfinzi* — resectable GC/GEJC
- **POTOMAC |** *Imfinzi* — non-muscle invasive bladder cancer
- **CAPItello280 |** *Truqap* — mCRPC
- **SERENA-6 |** camizestrant — 1L *ESR1*m HR+ HER2- adv. breast cancer
- **KALOS/LOGOS |** *Breztri* — uncontrolled asthma
- **CALYPSO |** eneboparatide — hypoparathyroidism

H2 2025

- **TROPION-Breast02 |** *Datroway* — 1L TNBC
- **DESTINY-Breast05 |** *Enhertu* — early HER2+ breast cancer
- **FLAURA2 OS |** *Tagrisso* — 1L *EGFR*m NSCLC
- **LATIFY |** ceralasertib + *Imfinzi* — post-IO NSCLC
- **RESOLUTE |** *Fasenra* — moderate to severe COPD
- **TULIP-SC |** *Saphnelo* — moderate to severe SLE
- **BaxHTN/Bax24|** baxdrostat — uncontrolled hypertension
- **TMA-313 |** *Ultomiris* — HSCT-TMA (adults)
- **CARES |** anselamimab — light chain (AL) amyloidosis
- **PREVAIL |** gefurulimab — generalised myasthenia gravis

H1 2026

- **AVANZAR |** *Datroway* + *Imfinzi* — 1L NSQ/NSQ TROP2+ NSCLC
- **TROPION-Lung07 |** *Datroway* — 1L NSQ NSCLC
- **EMERALD-3 |** *Imfinzi* + *Imjudo* — locoregional HCC
- **VOLGA |** *Imfinzi* ± *Imjudo* — muscle-invasive bladder cancer
- **SAFFRON |** *Tagrisso* + *Orpathys* — 2L *EGFR*m NSCLC
- **CLARITY-Gastric01 |** sonesitatug vedotin — 2L+ CLDN18.2+ gastric cancer
- **OBERON/TITANIA |** tozorakimab — COPD
- **MIRANDA |** tozorakimab — COPD
- **ICAN |** *Ultomiris* — IgAN
- **HICKORY/CHESTNUT/MULBERRY|** efzimfotase alfa - hypophosphatasia

H2 2026

- **TROPION-Lung15 |** *Datroway* ± *Tagrisso* 2L *EGFR*m NSCLC
- **EMERALD-2 |** *Imfinzi* — early HCC
- **PACIFIC-9 |** *Imfinzi* + oleclumab/ monalizumab — unresect. stg. III NSCLC
- **SERENA-4 |** camizestrant — 1L HR+ HER2- met. breast cancer
- **IRIS |** *Saphnelo* — lupus nephritis
- **DAISY |** *Saphnelo* — systemic sclerosis
- **CROSSING |** *Tezspire* — eosinophilic esophagitis (EoE)
- **CARDIO-TTRansform |** *Wainua* — ATTR-CM
- **TILIA |** tozorakimab — lower respiratory tract disease
- **ARTEMIS |** *Ultomiris* — CSA-AKI

● Primary/key secondary endpoint met ● Primary endpoint not met ● Primary endpoint not met in overall patient population; highly clinically meaningful improvement demonstrated in a prespecified subgroup of patients

Key upcoming pipeline catalysts are defined by a threshold of non-risk adjusted global peak year revenue expectations as of 6 November 2025.

Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Hutchmed (*Orpathys*), Ionis (*Wainua*), Amgen (*Tezspire*), Compugen (rilvegostomig), Merck & Co., Inc. (*Lynparza*), Innate Pharma (monalizumab).

Appendix: Glossary.

Oncology | BioPharma | Rare

Investing in transformative technologies to underpin our next wave of growth beyond 2030

Weight management and risk factors

Establish and lead in new weight management paradigm

3 Phase III trials ongoing with **laroprovstat**

Multiple Phase II trials to readout in 2026

AZD5004
AZD6234
AZD9550 + AZD6234

ADCs and Radioconjugates

Replace systemic chemotherapy and radiotherapy

sone-vedo Phase III readout expected H1 2026

puxi-sam in Phase III and **AZD5335** to enter by YE

FPI-2265 Phase II for pre-treated mCRPC

Next-gen IO bispecifics

Replace existing PD-1/ PD-L1 inhibitors

14 Phase III trials with rilvegostomig and volrustomig initiated[1]

Encouraging early evidence for **ADC combination** presented at ASCO and ESMO 2025

Cell therapy and T-cell engagers

Develop scalable cell therapies and T-cell engagers across therapy areas

AZD0120 and **surovatamig** early data at ASH 2025

surovatamig Phase III ongoing in 1L FL

AZD0120 Phase III planned in multiple myeloma

Gene therapy and gene editing

Make cure possible for a range of rare diseases

ALXN2350 (AAV gene therapy) Phase I initiated in BAG3 mutation associated dilated cardiomyopathy

Accelerating programs into late-stage development to drive 2030+ growth

1. Does not include eVOLVE-RCC02 which remains in Phase Ib.
Updated as of 6 November 2025.
Collaboration partner: Compugen (rilvegostomig).
Appendix: Glossary.



Q&A Session

Pascal Soriot
CHIEF EXECUTIVE OFFICER

Aradhana Sarin
CHIEF FINANCIAL OFFICER

Marc Dunoyer
CHIEF EXECUTIVE OFFICER, ALEXION

Susan Galbraith
EVP, ONCOLOGY HAEMATOLOGY R&D

Dave Fredrickson
EVP, ONCOLOGY HAEMATOLOGY BUSINESS

Sharon Barr
EVP, BIOPHARMACEUTICALS R&D

Ruud Dobber
EVP, BIOPHARMACEUTICALS BUSINESS

Iskra Reic
EVP, INTERNATIONAL

Appendix

AstraZeneca P&L reference table

P&L line-item definitions

	P&L line-item definition
Product Sales	• Recognises sales from territories where Group has lead commercialisation • Recognises supply of *Beyfortus* to Sanofi
Alliance Revenue	• Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place[1]
Product Revenue	• The sum of Product Sales and Alliance Revenue
Collaboration Revenue	• Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product
Total Revenue	• Sum of Product Sales, Alliance Revenue and Collaboration Revenue
Gross Margin	• Calculated by dividing Gross Profit by Total Revenue
Other operating income & expense	• Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest
Core[2] Operating margin	• Defined as Core Operating profit as a percentage of Total Revenue

1. Partnered medicines include: *Enhertu*, *Lynparza, Datroway*, *Beyfortus*, *Tezspire*, *Wainua*. 2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges.
Appendix: Glossary.

AstraZeneca in non-small cell lung cancer



All numbers are approximate. Illustrative settings and populations, not to scale. Lung Cancer map reflects Phase III/pivotal trials.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Hutchmed (*Orpathys*), Compugen (rilvegostomig).
Appendix: Glossary.

AstraZeneca in breast cancer



29 All numbers are approximate. Illustrative settings and populations, not to scale. Breast Cancer map reflects Phase III/pivotal trials.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

AstraZeneca in gastric cancer



sonesitatug vedotin previously AZD0901.

All numbers are approximate. Illustrative settings and populations, not to scale. Gastric cancer map reflects ongoing active Phase III/pivotal trials.

Collaboration partners: Daiichi Sankyo (*Enhertu*), Compugen (rilvegostomig).

Appendix: Glossary.

Oncology

Tagrisso

10% growth at CER to $5,352m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	409	360	488	432	446	391	519	489	501
ERoW	198	163	182	191	186	201	175	209	207
Europe	281	299	302	327	328	344	307	351	372
US	577	597	623	658	714	767	678	761	784

Lynparza

7% growth at CER to $2,401m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	131	133	167	153	155	180	161	162	164
ERoW	71	65	59	66	62	66	57	69	66
Europe	178	191	191	206	214	220	196	229	242
US	322	352	288	319	347	378	312	378	365

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology

Imfinzi

25% growth at CER to $4,317m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	86	87	129	117	120	113	142	152	169
ERoW	207	213	170	183	167	167	139	174	178
Europe	203	207	232	227	236	253	252	285	342
US	570	570	582	620	680	721	728	844	912

Imjudo

21% growth at CER to $253m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	1	3	4	4	4	5	5	7	6
ERoW	14	12	11	13	12	13	11	13	10
Europe	5	5	8	8	10	10	11	12	13
US	40	38	39	49	46	45	53	57	55

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Oncology

Calquence

10% growth at CER to $2,551m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	28	29	39	36	41	37	54	49	61
ERoW	30	28	32	33	33	31	31	42	43
Europe	128	140	153	167	169	167	170	198	200
US	468	478	494	554	570	573	507	583	612

Enhertu

38% growth at CER to $1,976m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	72	74	112	112	128	125	172	192	225
ERoW	9	15	13	19	16	22	19	23	21
Europe	79	91	134	129	136	142	146	166	177
US	179	184	202	212	229	250	258	284	291

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

BioPharmaceuticals: Cardiovascular, Renal & Metabolism

Farxiga

11% growth at CER to $6,345m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	577	559	711	763	750	628	871	859	893
ERoW	104	72	109	104	108	103	121	107	103
Europe	506	525	553	680	670	731	683	765	698
US	366	451	473	394	411	472	383	420	441

Brilinta

33% decrease at CER to $665m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	64	61	88	78	66	62	74	63	66
ERoW	6	6	5	4	5	6	3	2	2
Europe	68	68	67	69	67	65	55	51	23
US	193	194	163	191	189	208	173	99	55

Lokelma

31% growth at CER to $517m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	13	13	21	21	26	18	30	33	36
ERoW	22	24	23	28	26	31	28	37	36
Europe	16	17	18	23	25	26	26	30	35
US	51	58	52	64	66	75	69	75	82

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Fasenra

19% growth at CER to $1,451m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	19	16	22	19	27	23	27	26	28
ERoW	35	36	33	37	36	39	39	44	50
Europe	86	93	93	99	102	110	103	125	122
US	249	275	210	268	271	299	249	307	330

Tezspire

63% growth at CER to $770m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	0	1	2	3	3	4	7	9	8
ERoW	10	14	14	19	22	25	23	31	32
Europe	11	17	27	35	43	51	57	72	79
US	74	83	77	104	123	133	130	155	168

Saphnelo

47% growth at CER to $483m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	0	1	1	1	3	2	3	4	4
ERoW	3	3	3	4	4	5	4	6	7
Europe	2	3	4	6	7	9	9	12	13
US	71	82	83	101	110	131	120	145	156

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Amgen (*Tezspire*).
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Breztri

26% growth at CER to $906m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	42	38	70	61	68	45	90	65	83
ERoW	12	15	14	19	19	21	20	25	24
Europe	19	26	30	35	37	42	42	46	49
US	98	120	105	120	142	149	148	147	167

Symbicort

0% decrease at CER to $2,180m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	195	153	253	197	203	153	232	168	224
ERoW	81	88	75	83	83	88	77	91	78
Europe	123	142	142	143	130	144	135	137	135
US	156	137	299	299	289	299	279	319	305

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Rare Disease

Ultomiris

21% growth at CER to $3,453m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	17	24	32	35	26	49	52	61	64
ERoW	131	138	143	152	170	173	166	179	200
Europe	184	173	202	209	238	235	228	270	271
US	445	490	482	550	597	632	604	667	690

Strensiq

19% growth at CER to $1,188m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	5	11	21	10	8	15	34	16	11
ERoW	21	22	22	23	24	27	26	29	29
Europe	22	25	24	24	25	26	26	31	32
US	237	247	246	283	286	352	266	319	369

Koselugo

34% growth at CER to $498m in 9M 2025



	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
EM	11	10	59	24	25	69	40	36	113
ERoW	7	9	9	9	10	11	11	12	16
Europe	15	15	18	26	29	29	34	37	44
US	54	51	46	55	55	56	53	52	51

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Merck & Co., Inc. (*Koselugo*) concluded in August 2025.
Appendix: Glossary.

Glossary

1L, 2L, 3L	first-, second-, third-line
9M	nine months
AANEM	American Association of Neuromuscular & Electrodiagnostic Medicine
AAV	adeno-associated virus
ADC	antibody-drug conjugate
adv.	advanced
AHA	American Heart Association
AI	aromatase inhibitor
AKT1	AKT serine/threonine kinase 1
ASCO	American Society of Clinical Oncology
ASH	American Society of Hematology
ASI	aldosterone synthase inhibitor
ATTR-CM	transthyretin amyloid cardiomyopathy
AZ	AstraZeneca
BC	breast cancer
BCG	Bacillus Calmette-Guérin
BTKi	Bruton's tyrosine kinase
C5	complement component 5
CapEx	capital expenditure
CDK4/6i	cyclin-dependent kinase 4/6 inhibitor
CER	constant exchange rates
CFO	net cash inflow from operating activities
CKD	chronic kidney disease
CLDN18.2	Claudin-18.2
CLL	chronic lymphocytic leukaemia
CN	China
COPD	chronic obstructive pulmonary disease
CR	Collaboration Revenue
CRT	chemoradiotherapy
CSA-AKI	cardiac surgery associated acute kidney injury
CTx	chemotherapy
CV	cardiovascular
CVRM	Cardiovascular, Renal and Metabolism
DFS	disease free survival
Dxd	deruxtecan
eBC	early breast cancer
EBITDA	earnings before interest, tax, depreciation and amortisation
EFS	event-free survival
EGFRm	epidermal growth factor receptor-mutant
EGPA	eosinophilic granulomatosis with polyangiitis
EoE	eosinophilic esophagitis
epi	epidemiology
EPS	earnings per share
ERoW	Established Rest of World
ESC	European Society of Cardiology
ESMO	European Society of Medical Oncology
ESR1m	estrogen receptor alpha-mutated
EU	Europe
FDC	fixed-dose combination
FL	follicular lymphoma
FLOT	fluorouracil, leucovorin, oxaliplatin and docetaxel
FP	fluoropyrimidine
FX	foreign exchange
FY	Fiscal Year
G7	US, Japan, EU5
gBRCAm	germline BRCA-mutated breast cancer
GC	gastric cancer
GEJC	gastroesophageal junction cancer
GM	General Meeting
gMG	generalised myasthenia gravis
HCC	hepatocellular carcinoma
HER2-/negative	human epidermal growth factor receptor 2-negative
HER2+/positive	human epidermal growth factor receptor 2-positive
HER2-low	human epidermal growth factor receptor 2-low
HER2m	human epidermal growth factor receptor 2-mutant
HER2-ultralow	human epidermal growth factor receptor 2-ultralow
HF	heart failure
HPP	hypophosphatasia
HR+/positive	hormone receptor-positive
HSCT-TMA	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
i.v.	intravenous
I+M	induction + maintenance
IgAN	Immunoglobulin A nephropathy
IL-5	interleukin-5
IO	immuno-oncology
JP	Japan
K+	potassium
LSM	least-squares mean
mCRPC	metastatic castration-resistant prostate cancer
MFN	most favoured nations
mg	milligram
MG-ADL	Myasthenia Gravis Activities of Daily Living
mmHg	millimetres of mercury
mOS	median overall survival
NF-1-PN	Neurofibromatosis Type 1 Plexiform Neurofibromas
NME	new molecular entity
NMIBC	non-muscle invasive bladder cancer
NMOSD	neuromyelitis optica spectrum disorder
NMR+	normalised membrane ratio positive
NRDL	national reimbursement drug list
NSCLC	non-small cell lung cancer
NSQ	non-squamous
NST	neoadjuvant systemic treatment
NYSE	New York Stock Exchange
OLE	open label extension
ORR	objective response rate
OS	overall survival
PALB2m	partner and localizer of BRCA2
PARPi	poly-ADP ribose polymerase inhibitor
pCR	pathologic complete response
PD-1	programmed cell death protein 1
PD-L1	programmed cell death ligand 1
PDx	PD-(L)1 inhibitor
PIK3CA	phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit
PNH	paroxysmal nocturnal haemoglobinuria
PR	Product Revenue
PS	Product Sales
PTEN	phosphatase and TENsin homolog deleted on chromosome 10
PYR	Peak-Year Revenue
R&D	Research & Development
R&I	Respiratory & Immunology
RCT	randomised control trial
SBP	systolic blood pressure
SBRT	stereotactic body radiotherapy
SG&A	Selling, General & Administrative
SLE	systemic lupus erythematosus
SoC	standard-of-care
SQ	squamous
Stg.	stage
tBRCAm	tumor BRCA mutation
T-DM1	trastuzumab emtansine
THP	docetaxel, trastuzumab and pertuzumab
TIGIT	T-cell immunoreceptor with immunoglobulin and ITIM domains
TKI	tyrosine kinase inhibitor
TL07	TROPION-Lung07
TL08	TROPION-Lung08
TNBC	triple negative breast cancer
US	United States
V&I	Vaccines & Immune Therapies
WCLC	World Conference on Lung Cancer
YTD	year to date

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK
+44(0)203 749 5000
www.astrazeneca.com